{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T04:44:24Z","timestamp":1666845864795},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00108-022-01394-w","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T12:07:34Z","timestamp":1663675654000},"page":"1148-1160","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapie der chronischen Herzinsuffizienz \u2013 State of the Art nach den europ\u00e4ischen Leitlinien von 2021"],"prefix":"10.1007","volume":"63","author":[{"given":"Kristian","family":"Hellenkamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslava","family":"Valentova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"1394_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart\u00a0J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"1394_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P, Voors\u00a0AA, Anker\u00a0SD et\u00a0al (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 18:891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592","journal-title":"Eur J Heart Fail"},{"key":"1394_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","volume":"19","author":"G Savarese","year":"2022","unstructured":"Savarese\u00a0G, Stolfo\u00a0D, Sinagra\u00a0G, Lund\u00a0LH (2022) Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol 19:100\u2013116. https:\/\/doi.org\/10.1038\/s41569-021-00605-5","journal-title":"Nat Rev Cardiol"},{"key":"1394_CR4","doi-asserted-by":"crossref","unstructured":"CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316(23):1429\u20131435","DOI":"10.1056\/NEJM198706043162301"},{"key":"1394_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"SOLVD Investigators, Yusuf\u00a0S, Pitt\u00a0B et\u00a0al (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N\u00a0Engl J Med 325:293\u2013302. https:\/\/doi.org\/10.1056\/NEJM199108013250501","journal-title":"N Engl J Med"},{"key":"1394_CR6","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer\u00a0M, Bristow\u00a0MR, Cohn\u00a0JN et\u00a0al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N\u00a0Engl J Med 334:1349\u20131355. https:\/\/doi.org\/10.1056\/NEJM199605233342101","journal-title":"N Engl J Med"},{"key":"1394_CR7","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"344","author":"M Packer","year":"2001","unstructured":"Packer\u00a0M, Coats\u00a0AJ, Fowler\u00a0MB et\u00a0al (2001) Effect of carvedilol on survival in severe chronic heart failure. N\u00a0Engl J Med 344:1651\u20131658. https:\/\/doi.org\/10.1056\/NEJM200105313442201","journal-title":"N Engl J Med"},{"key":"1394_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","unstructured":"CIBIS-II Investigators and Committees (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a\u00a0randomised trial. Lancet 353:9\u201313","journal-title":"Lancet"},{"key":"1394_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"MERIT-HF Study Group","year":"1999","unstructured":"MERIT-HF Study Group (1999) Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet 353:2001\u20132007. https:\/\/doi.org\/10.1016\/S0140-6736(99)04440-2","journal-title":"Lancet"},{"key":"1394_CR10","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","volume":"283","author":"A Hjalmarson","year":"2000","unstructured":"Hjalmarson\u00a0A, Goldstein\u00a0S, Fagerberg\u00a0B et al (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group. JAMA 283:1295\u20131302. https:\/\/doi.org\/10.1001\/jama.283.10.1295","journal-title":"JAMA"},{"key":"1394_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt\u00a0B, Zannad\u00a0F, Remme\u00a0WJ et\u00a0al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N\u00a0Engl J Med 341:709\u2013717. https:\/\/doi.org\/10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"1394_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad\u00a0F, McMurray\u00a0JJV, Krum\u00a0H et\u00a0al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N\u00a0Engl J Med 364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"1394_CR13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2019.0693","volume":"321","author":"DL Packer","year":"2019","unstructured":"Packer\u00a0DL, Mark\u00a0DB, Robb\u00a0RA et\u00a0al (2019) Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 321:1261\u20131274. https:\/\/doi.org\/10.1001\/jama.2019.0693","journal-title":"JAMA"},{"key":"1394_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE et\u00a0al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"1394_CR15","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J et\u00a0al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N\u00a0Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"1394_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12181-022-00543-7","author":"S Frantz","year":"2022","unstructured":"Frantz\u00a0S, Anker\u00a0S, Bauersachs\u00a0J et\u00a0al (2022) Kommentar zu den Leitlinien (2021) der ESC zur Diagnose und Behandlung akuter und chronischer Herzinsuffizienz. Kardiologe. https:\/\/doi.org\/10.1007\/s12181-022-00543-7","journal-title":"Kardiologe"},{"key":"1394_CR17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger\u00a0CB, McMurray\u00a0JJV, Yusuf\u00a0S et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772\u2013776. https:\/\/doi.org\/10.1016\/S0140-6736(03)14284-5","journal-title":"Lancet"},{"key":"1394_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJM199807303390507","volume":"339","author":"ER Levin","year":"1998","unstructured":"Levin\u00a0ER, Gardner\u00a0DG, Samson\u00a0WK (1998) Natriuretic peptides. N\u00a0Engl J Med 339:321\u2013328. https:\/\/doi.org\/10.1056\/NEJM199807303390507","journal-title":"N Engl J Med"},{"key":"1394_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray\u00a0JJV, Packer\u00a0M, Desai\u00a0AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"1394_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez\u00a0EJ, Morrow\u00a0DA, DeVore\u00a0AD et al (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N\u00a0Engl J Med 380:539\u2013548. https:\/\/doi.org\/10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"1394_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10146-1","author":"A Aimo","year":"2021","unstructured":"Aimo\u00a0A, Castiglione\u00a0V, Vergaro\u00a0G et\u00a0al (2021) The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail Rev. https:\/\/doi.org\/10.1007\/s10741-021-10146-1","journal-title":"Heart Fail Rev"},{"key":"1394_CR22","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong\u00a0PW, Pieske\u00a0B, Anstrom\u00a0KJ et\u00a0al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 382:1883\u20131893. https:\/\/doi.org\/10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"1394_CR23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","volume":"375","author":"L K\u00f8ber","year":"2016","unstructured":"K\u00f8ber\u00a0L, Thune\u00a0JJ, Nielsen\u00a0JC et\u00a0al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N\u00a0Engl J Med 375:1221\u20131230. https:\/\/doi.org\/10.1056\/NEJMoa1608029","journal-title":"N Engl J Med"},{"key":"1394_CR24","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ejhf.1236","volume":"20","author":"MG Crespo-Leiro","year":"2018","unstructured":"Crespo-Leiro\u00a0MG, Metra\u00a0M, Lund\u00a0LH et al (2018) Advanced heart failure: a\u00a0position statement of the heart failure association of the European Society of Cardiology. Eur J Heart Fail 20:1505\u20131535. https:\/\/doi.org\/10.1002\/ejhf.1236","journal-title":"Eur J Heart Fail"},{"key":"1394_CR25","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof\u00a0P, Camm\u00a0AJ, Goette\u00a0A et al (2020) Early rhythm-control therapy in patients with atrial fibrillation. N\u00a0Engl J Med 383:1305\u20131316. https:\/\/doi.org\/10.1056\/NEJMoa2019422","journal-title":"N Engl J Med"},{"key":"1394_CR26","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jama.2019.0692","volume":"321","author":"DB Mark","year":"2019","unstructured":"Mark\u00a0DB, Anstrom\u00a0KJ, Sheng\u00a0S et\u00a0al (2019) Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 321:1275\u20131285. https:\/\/doi.org\/10.1001\/jama.2019.0692","journal-title":"JAMA"},{"key":"1394_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1707855","volume":"378","author":"NF Marrouche","year":"2018","unstructured":"Marrouche\u00a0NF, Brachmann\u00a0J, Andresen\u00a0D et\u00a0al (2018) Catheter ablation for atrial fibrillation with heart failure. N\u00a0Engl J Med 378:417\u2013427. https:\/\/doi.org\/10.1056\/NEJMoa1707855","journal-title":"N Engl J Med"},{"key":"1394_CR28","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","volume":"143","author":"DL Packer","year":"2021","unstructured":"Packer\u00a0DL, Piccini\u00a0JP, Monahan\u00a0KH et\u00a0al (2021) Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation 143:1377\u20131390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050991","journal-title":"Circulation"},{"key":"1394_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab395","author":"A Vahanian","year":"2021","unstructured":"Vahanian\u00a0A, Beyersdorf\u00a0F, Praz\u00a0F et al (2021) 2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS). Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab395","journal-title":"Eur Heart J"},{"key":"1394_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00108-016-0033-y","volume":"57","author":"M Puls","year":"2016","unstructured":"Puls\u00a0M, Schillinger\u00a0W (2016) Catheter-based mitral valve repair by MitraClip implantation: development, studies, and use in clinical practice. Internist (Berl) 57:323\u2013331. https:\/\/doi.org\/10.1007\/s00108-016-0033-y","journal-title":"Internist (Berl)"},{"key":"1394_CR31","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","volume":"379","author":"J-F Obadia","year":"2018","unstructured":"Obadia\u00a0J\u2011F, Messika-Zeitoun\u00a0D, Leurent\u00a0G et al (2018) Percutaneous repair or medical treatment for secondary mitral regurgitation. N\u00a0Engl J Med 379:2297\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1805374","journal-title":"N Engl J Med"},{"key":"1394_CR32","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone\u00a0GW, Lindenfeld\u00a0J, Abraham\u00a0WT et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N\u00a0Engl J Med 379:2307\u20132318. https:\/\/doi.org\/10.1056\/NEJMoa1806640","journal-title":"N Engl J Med"},{"key":"1394_CR33","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker\u00a0SD, Comin Colet\u00a0J, Filippatos\u00a0G et\u00a0al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N\u00a0Engl J Med 361:2436\u20132448. https:\/\/doi.org\/10.1056\/NEJMoa0908355","journal-title":"N Engl J Med"},{"key":"1394_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski\u00a0P, van Veldhuisen\u00a0DJ, Comin-Colet\u00a0J et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020. Eur Heart\u00a0J 36:657\u2013668. https:\/\/doi.org\/10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"key":"1394_CR35","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","volume":"136","author":"DJ van Veldhuisen","year":"2017","unstructured":"van Veldhuisen\u00a0DJ, Ponikowski\u00a0P, van der Meer\u00a0P et\u00a0al (2017) Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 136:1374\u20131383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.027497","journal-title":"Circulation"},{"key":"1394_CR36","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski\u00a0P, Kirwan\u00a0B\u2011A, Anker\u00a0SD et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a\u00a0multicentre, double-blind, randomised, controlled trial. Lancet 396:1895\u20131904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"1394_CR37","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G et\u00a0al (2021) Empagliflozin in heart failure with a\u00a0preserved ejection fraction. N\u00a0Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"1394_CR38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler\u00a0J, Packer\u00a0M, Filippatos\u00a0G et\u00a0al (2022) Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart\u00a0J 43:416\u2013426. https:\/\/doi.org\/10.1093\/eurheartj\/ehab798","journal-title":"Eur Heart J"},{"key":"1394_CR39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","volume":"145","author":"J Butler","year":"2022","unstructured":"Butler\u00a0J, Filippatos\u00a0G, Jamal Siddiqi\u00a0T et al (2022) Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial. Circulation 145:184\u2013193. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057812","journal-title":"Circulation"},{"key":"1394_CR40","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif\u00a0ME, Windsor\u00a0SL, Borlaug\u00a0BA et\u00a0al (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a\u00a0multicenter randomized trial. Nat Med 27:1954\u20131960. https:\/\/doi.org\/10.1038\/s41591-021-01536-x","journal-title":"Nat Med"},{"key":"1394_CR41","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1007\/s13300-020-00911-0","volume":"11","author":"DM Williams","year":"2020","unstructured":"Williams\u00a0DM, Evans\u00a0M (2020) Dapagliflozin for heart failure with preserved ejection fraction: will the DELIVER study deliver? Diabetes Ther 11:2207\u20132219. https:\/\/doi.org\/10.1007\/s13300-020-00911-0","journal-title":"Diabetes Ther"},{"key":"1394_CR42","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","volume":"20","author":"LH Lund","year":"2018","unstructured":"Lund\u00a0LH, Claggett\u00a0B, Liu\u00a0J et al (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20:1230\u20131239. https:\/\/doi.org\/10.1002\/ejhf.1149","journal-title":"Eur J Heart Fail"},{"key":"1394_CR43","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Anand\u00a0IS et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N\u00a0Engl J Med 381:1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"1394_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.02.009","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich\u00a0PA, Bozkurt\u00a0B, Aguilar\u00a0D et\u00a0al (2022) 2022 American College of Cardiology\/American Heart Association\/Heart Failure Society of America guideline for the management of heart failure: executive summary. J\u00a0Card Fail. https:\/\/doi.org\/10.1016\/j.cardfail.2022.02.009","journal-title":"J Card Fail"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01394-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01394-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01394-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T12:04:32Z","timestamp":1666785872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01394-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1394"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01394-w","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"4 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>K.\u00a0Hellenkamp<\/b>: A.\u00a0Finanzielle Interessen: Aktuell Forschungsf\u00f6rderung f\u00fcr ein wissenschaftliches Projekt bei AstraZeneca beantragt; m\u00f6gliche finanzielle Unterst\u00fctzung in den n\u00e4chsten 12\u00a0Monaten.\u00a0\u2013 Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Bayer, Diaplan (f\u00fcr Berufsverband Deutscher Internistinnen und Internisten [BDI]), AstraZeneca.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Kardiologe (Oberarzt), Klinik f\u00fcr Kardiologie und Pneumologie\/Herzzentrum, Universit\u00e4tsmedizin G\u00f6ttingen | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Kardiologie (DGK), Arbeitsgruppe Kardiovaskul\u00e4re Intensiv- und Notfallmedizin (AG\u00a03)\u00a0\u2013 Cluster\u00a0A, Arbeitsgruppe Interventionelle Kardiologie (AG\u00a06)\u00a0\u2013 AGIK, Arbeitsgruppe Chronische Herzinsuffizienz (AG\u00a010); Europ\u00e4ische Gesellschaft f\u00fcr Kardiologie (ESC); Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM); Deutsche Gesellschaft f\u00fcr Internistische Intensivmedizin und Notfallmedizin (DGIIN).<b> M.\u00a0Valentova<\/b>: A.\u00a0Finanzielle Interessen: Advisory Board, Amomed Pharma GmbH, November 2019; Referentin, Bayer GmbH, Mai 2022.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenz\u00e4rztin, Klinik f\u00fcr Kardiologie und Pneumologie, Universit\u00e4tsmedizin G\u00f6ttingen | Mitgliedschaften: DGK, ESC.<b> S.\u00a0von Haehling<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung e.\u202fV. (DZHK), Europ\u00e4ische Kommission (EC), Volkswagenstiftung.\u00a0\u2013 Honorare f\u00fcr Vertr\u00e4ge von Bayer, Boehringer Ingelheim, Brahms, Chugai, Gr\u00fcnenthal, Helsinn, Hexal, Novartis, Respicardia, Roche, Sorin und Vifor.\u00a0\u2013 Beratert\u00e4tigkeiten f\u00fcr Bayer, Boehringer Ingelheim, Brahms, Chugai, Gr\u00fcnenthal, Helsinn, Hexal, Novartis, Respicardia, Roche, Sorin und Vifor.\u00a0\u2013 Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00c4. an einer im Medizinbereich aktiven Firma: Anteile von Actimed.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Kardiologe, Klinik f\u00fcr Kardiologie und Pneumologie, Universit\u00e4tsmedizin G\u00f6ttingen | Mitgliedschaften: ESC, Heart Failure Association.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}